Luga Podesta, MD, is a sports medicine and regenerative orthopedic specialist at Bluetail Medical Group in Naples, Fla. He was the lead author in a 2013 study in The American Journal of Sports Medicine which demonstrated that platelet-rich plasma can effectively treat partial UCL tears in athletes. In a recent interview with Becker's Spine Review, Dr. Podesta spoke about the possibilities and pitfalls of stem cell therapies in orthopedics and trends in regenerative medicine.

The global orthobiologics market is expected to grow from $4.66 billion in 2017 to reach $8.06 billion by 2023, increasing at a 5.7 percent compound annual growth rate, according to a Market.Biz report.

U.K.-based Tissue Regenix Group inked a deal with Premier for TRX's flagship product DermaPure to maintain access to 3,900 hospitals and more than 150,000 healthcare providers in the U.S., according to proactiveinvestors UK.

Biologica Technologies will exhibit clinical data for its ProteiOS growth factor at the American Association of Neurological Surgeons Annual Scientific Meeting in New Orleans.

Medtronic received FDA clearance for a new indication with its Infuse Bone Graft.

The phase I/II U.S. clinical trial testing DiscGenics' IDCT for treating degenerative disc disease is underway.

Datum Orthobiologics was recently founded to provide orthopedic ossification, bone formation and tissue regeneration solutions.

A Siberian tiger at the Szeged Zoo in Hungary received Lipogems stem cell therapy for a hip joint problem April 18, euronews.com reports.

Plano-based Texas Back Institute researchers are assessing the effectiveness of stem cells for revitalizing spinal tissue in a clinical trial.

A new class of clay nanoparticles can lead human mesenchymal stem cells to develop into bone or cartilage cells, Futurity reports.

SpinalCyte is a Houston-based tissue engineering company developing a spinal nucleus replacement solution using human dermal fibroblasts.

Kevin Plancher, MD, is a board-certified orthopedic surgeon and founder of Plancher Orthopaedics & Sports Medicine in New York City and Greenwich, Conn. Here are his insights on joint replacement versus growth factors and stem cell therapy for the treatment of hip and knee pain.

SpinalCyte filed an Investigational New Drug Application with the FDA to expand its study of CybroCell Human Dermal Fibroblasts for the treatment of degenerative disc disease.

The orthopedic biomaterials market is growing as the U.S. population ages, according to a Transparency Market Research report.

The American Academy of Orthopaedic Surgeons collaborated with the National Institutes of Arthritis, Musculoskeletal, and Skin Diseases to hold a symposium Feb. 15 through Feb. 17 at Stanford (Calif.) University on optimizing the use of biologics in orthopedic surgery.

The global spinal biologics market is expected to reach $2.4 billion by 2020, according to a MarketsandMarkets report. Here are eight companies leading the spinal biologics field.

Adam W. Anz, MD, is an orthopedic surgeon and sports medicine specialist at Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics & Sports Medicine. He is the director of the Andrews Institute Regenerative Medicine Center and oversees the ATC Fellowship Program at the Andrews Research & Education Foundation, where he serves as a board member.

RTI Surgical accomplished a major milestone in April.

Here are 14 developments in spinal biologics in 2018 so far.

Patients who received intradiscal injections of SpinalCyte's new cell-based therapy CybroCell showed significantly improved disc height after six months.